NF-κB in Mammary Gland Development and Breast Cancer (original) (raw)

REFERENCES

1. S. Ghosh and M. Karin (2002). Missing pieces in the NF-κB puzzle. Cell 109(Suppl):S81-S96.
   PubMed Google Scholar
2. M. Karin and A. Lin (2002). NF-κB at the crossroads of life and death. Nat. Immunol. 3:221–227.
   PubMed Google Scholar
3. D. M. Rothwarf and M. Karin (1999). The NF-κB activation pathway: A paradigm in information transfer from membrane to nucleus. Sci. STKE 1999:RE1.
   PubMed Google Scholar
4. M. J. May and S. Ghosh (1997). Rel/NF-κB and IκB proteins: An overview. Semin. Cancer Biol. 8:63–73.
   PubMed Google Scholar
5. I. Verma, J. Stevenson, E. Schwarz, D. Van Antwerp, and S. Miyamoto (1995). Rel/NF-κB/IκB family: Intimate tales of association and dissociation. Genes Dev. 9:2723–2735.
   PubMed Google Scholar
6. M. Karin and Y. Ben-Neriah (2000). Phosphorylation meets ubiquitination: The control of NF-[κ]B activity. Annu. Rev. Immunol. 18:621–663.
   PubMed Google Scholar
7. E. Dejardin, N. M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, et al. (2002). The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-κB pathways. Immunity 17: 525–535.
   PubMed Google Scholar
8. H. Pahl (1999). Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853–6866.
   PubMed Google Scholar
9. M. Karin, Y. Cao, F. R. Greten, and Z. W. Li (2002). NF-κB in cancer: From innocent bystander to major culprit. Nature Rev. Cancer 2:301–310.
   Google Scholar
10. B. Rayet and C. Gelinas (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938–6947.
    PubMed Google Scholar
11. T. Gilmore, M. Koedood, K. Piffat, and D. White (1996). Rel/NF-κB/IκB proteins and cancer. Oncogene 13: 1367–1378.
    PubMed Google Scholar
12. L. Hennighausen and G. W. Robinson (2001). Signaling pathways in mammary gland development. Dev. Cell 1:467–475.
    PubMed Google Scholar
13. L. Hennighausen and G. W. Robinson (1998). Think globally, act locally: The making of a mouse mammary gland. Genes Dev. 12: 449–455.
    PubMed Google Scholar
14. D. M. Brantley, F. E. Yull, R. S. Muraoka, D. J. Hicks, C. M. Cook, and L. D. Kerr (2000). Dynamic expression and activity of NF-κB during post-natal mammary gland morphogenesis. Mech. Dev. 97:149–155.
    PubMed Google Scholar
15. R. W. Clarkson, J. L. Heeley, R. Chapman, F. Aillet, R. T. Hay, A. Wyllie, et al. (2000). NF-κB inhibits apoptosis in murine mammary epithelia. J. Biol. Chem. 275: 12737–12742.
    PubMed Google Scholar
16. S. Geymayer and W. Doppler (2000). Activation of NF-κB p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression. FASEB J. 14:1159–1170.
    PubMed Google Scholar
17. D. M. Brantley, C. L. Chen, R. S. Muraoka, P. B. Bushdid, J. L. Bradberry, F. Kittrell, et al. (2001). Nuclear factor-κB (NF-κB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell 12:1445–1455.
    PubMed Google Scholar
18. Y. Cao, G. Bonizzi, T. N. Seagroves, F. R. Greten, R. Johnson, E. V. Schmidt, et al. (2001). IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107: 763–775.
    PubMed Google Scholar
19. J. M. Shillingford, K. Miyoshi, G. W. Robinson, B. Bierie, Y. Cao, M. Karin, et al. (2003). Proteotyping of mammary tissue from transgenic and gene knockout mice with immunohistochemical markers. A tool to define developmental lesions. J. Histochem. Cytochem. 51: 555–565.
    PubMed Google Scholar
20. G. Luo and L. Yu-Lee (2000). Stat5b inhibits NF-kB-mediated signaling. Mol. Endocrinol. 14: 114–123.
    PubMed Google Scholar
21. Y. Wang, T. R. Wu, S. Cai, T. Welte, and Y. E. Chin (2000). Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-κB activation. Mol. Cell. Biol. 20: 4505–4512.
    PubMed Google Scholar
22. R. W. Clarkson and C. J. Watson (1999). NF-κB and apoptosis in mammary epithelial cells. J. Mammary Gland Biol. Neoplasia 4:165–175.
    PubMed Google Scholar
23. L. E. Theill, W. J. Boyle, and J. M. Penninger (2002). RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20:795–823.
    PubMed Google Scholar
24. J. E. Fata, Y. Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R. A. Moorehead, et al. (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41–50.
    PubMed Google Scholar
25. L. Varela and M. Ip (1996). Tumor necrosis factor-alpha:A multifunctional regulator of mammary gland development. Endocrinology 137:4915–4924.
    PubMed Google Scholar
26. P. Sicinski, J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, et al. (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621–630.
    PubMed Google Scholar
27. V. Fantl, G. Stamp, A. Andrews, I. Rosewell, and C. Dickson (1995). Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:2364–2372.
    PubMed Google Scholar
28. O. N. Ozes, L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner (1999). NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82–85.
    PubMed Google Scholar
29. J. A. Romashkova and S. S. Makarov (1999). NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86–90.
    PubMed Google Scholar
30. K. L. Schwertfeger, M. M. Richert, and S. M. Anderson (2001). Mammary gland involution is delayed by activated Akt in transgenic mice. Mol. Endocrinol. 15:867–881.
    PubMed Google Scholar
31. J. Hutchinson, J. Jin, R. D. Cardiff, J. R. Woodgett, and W. J. Muller (2001). Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol. Cell. Biol. 21:2203–2212.
    PubMed Google Scholar
32. S. Gerondakis, M. Grossmann, Y. Nakamura, T. Pohl, and R. Grumont (1999). Genetic approaches in mice to understand Rel/NF-kB and IkB functions: Transgenics and knockouts. Oncogene 18:6888–6895.
    PubMed Google Scholar
33. A. A. Beg, W. C. Sha, R. T. Bronson, S. Ghosh, and D. Baltimore (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376:167–170.
    PubMed Google Scholar
34. Z. W. Li, W. Chu, Y. Hu, M. Delhase, T. Deerinck, M. Ellisman, et al. (1999). The IKKbeta subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J. Exp. Med. 189:1839–1845.
    PubMed Google Scholar
35. C. Makris, V. L. Godfrey, G. Krahn-Senftleben, T. Takahashi, J. L. Roberts, T. Schwarz, et al. (2000). Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell 5:969–979.
    PubMed Google Scholar
36. P. C. Cogswell, D. C. Guttridge, W. K. Funkhouser, and A. S. BaldwinJr. (2000). Selective activation of NF-κB subunits in human breast cancer: Potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 19:1123–1131.
    PubMed Google Scholar
37. H. Nakshatri, P. Bhat-Nakshatri, D. A. Martin, R. J. GouletJr., and G. W. SledgeJr. (1997). Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17:3629–3639.
    PubMed Google Scholar
38. M. A. Sovak, R. E. Bellas, D. W. Kim, G. J. Zanieski, A. E. Rogers, A. M. Traish, et al. (1997). Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100:2952–2960.
    PubMed Google Scholar
39. R. Romieu-Mourez, E. Landesman-Bollag, D. C. Seldin, A. M. Traish, F. Mercurio, and G. E. Sonenshein (2001). Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-κB in breast cancer. Cancer Res. 61:3810–3818.
    PubMed Google Scholar
40. D. W. Kim, M. A. Sovak, G. Zanieski, G. Nonet, R. Romieu-Mourez, A. W. Lau, et al. (2000). Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21:871–879.
    PubMed Google Scholar
41. D. K. Biswas, S. C. Dai, A. Cruz, B. Weiser, E. Graner, and A. B. Pardee (2001). The nuclear factor κB (NF-κB): A potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. U.S.A. 98:10386–10391.
    PubMed Google Scholar
42. M. A. Sovak, M. Arsura, G. Zanieski, K. T. Kavanagh, and G. E. Sonenshein (1999). The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-κB/Rel expression. Cell Growth Differ. 10:537–544.
    PubMed Google Scholar
43. E. Dejardin, G. Bonizzi, A. Bellahcene, V. Castronovo, M. P. Merville, and V. Bours (1995). Highly-expressed p100/p52 (NFKB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11:1835–1841.
    PubMed Google Scholar
44. S. D. Westerheide, M. W. Mayo, V. Anest, J. L. Hanson, and A. S. BaldwinJr. (2001). The putative oncopretein Bcl-3 induces cyclin D1 to stimulate G1 transition. Mol. Cell. Biol. 21:8428–8436.
    PubMed Google Scholar
45. N. J. Solan, H. Miyoshi, G. D. Bren, and C. V. Paya (2002). RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem. 277:1405–1418.
    PubMed Google Scholar
46. D. W. Kim, L. Gazourian, S. A. Quadri, R. Romieu-Mourez, D. H. Sherr, and G. E. Sonenshein (2000). The RelA NF-κB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 19:5498–5506.
    PubMed Google Scholar
47. E. L. Lagow and D. D. Carson (2002). Synergistic stimulation of MUC1 expression in normal breast epithelial and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J. Cell Biochem 86:759–772.
    PubMed Google Scholar
48. V. Deregowski, S. Delhalle, V. Benoit, V. Bours, and M. P. Merville (2002). Identification of cytokine-induced nuclear factor-κB target genes in ovarian and breast cancer cells. Biochem. Pharmacol. 64:873–881.
    PubMed Google Scholar
49. T. S. Finco, J. K. Westwick, J. L. Norris, A. A. Beg, C. J. Der, and A. S. Baldwin Jr. (1997). Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272:24113–24116.
    PubMed Google Scholar
50. H. Jo, R. Zhang, H. Zhang, T. A. McKinsey, J. Shao, R. D. Beauchamp, et al. (2000). NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene 19:841–849.
    PubMed Google Scholar
51. S. Pianetti, M. Arsura, R. Romieu-Mourez, R. J. Coffey, and G. E. Sonenshein (2001). Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287–1299.
    PubMed Google Scholar
52. B. P. Zhou, M. C. Hu, S. A. Miller, Z. Yu, W. Xia, S. Y. Lin, et al. (2000). HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem. 275:8027–8031.
    PubMed Google Scholar
53. L. T. Amundadottir and P. Leder (1998). Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 16:737–746.
    PubMed Google Scholar
54. P. Bhat-Nakshatri, C. J. Sweeney, and H. Nakshatri (2002). Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells. Oncogene 21:2066–2078.
    PubMed Google Scholar
55. D. C. Guttridge, C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. BaldwinJr. (1999). NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:5785–5799.
    PubMed Google Scholar
56. M. Hinz, D. Krappmann, A. Eichten, A. Heder, C. Scheidereit, and M. Strauss (1999). NF-κB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19:2690–2698.
    PubMed Google Scholar
57. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669–671.
    PubMed Google Scholar
58. Q. Yu, Y. Geng, and P. Sicinski (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017–1021.
    PubMed Google Scholar
59. I. Eto (2000). Molecular cloning and sequence analysis of the promoter region of mouse cyclin D1 gene: implication in phorbol ester-induced tumour promotion. Cell Prolif. 33:167–187.
    PubMed Google Scholar

Download references